Skip to main content
Top

Open Access 21-04-2025 | Psoriatic Arthritis | BRIEF REPORT

The VITACORA- 19 and PsAID questionnaires are equally valid for assessing the impact of psoriatic arthritis on patients' quality of life

Authors: Ignacio Braña, Marta Loredo, Juan Carlos Torre-Alonso, Rubén Queiro

Published in: Clinical Rheumatology

Login to get access

Abstract

Background and aims

Health-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA). We aimed to compare the VITACORA-19 and PsAID (Psoriatic Arthritis Impact of Disease) questionnaires to assess QoL in routine PsA management.

Methods

Cross-sectional analysis of a randomly selected PsA population. Disease activity was estimated using the DAPSA (Disease Activity score for PsA) index and HRQoL using the VITACORA-19 and PsAID. The construct validity of VITACORA-19 was analysed (Pearson correlation and ROC curves).

Results

Forty-five patients were included, 24 men and 21 women, mean age 55 ± 13 years, mean disease duration 8.2 ± 6.1 years. Most patients showed adequate disease control, median DAPSA 11.3 (IQR: 8.0–19.3), median PsAID 2.7 (IQR: 1.1–5.0). VITACORA-19 scores ranged from 6 to 94. The correlation between VITACORA-19 and PsAID was high, r: -0.7 (95%CI: -0.84 to -0.46), p < 0.0001. A VITACORA-19 score in the range of 6–29 corresponded to high DAPSA disease activity, a range of 30–44 corresponded to moderate DAPSA activity and a range of 45–95 corresponded to low DAPSA activity. The cut-off for an acceptable symptomatic state (PsAID < 4) corresponded to a VITACORA-19 score ≥ 66 with an area under the ROC curve of 0.85 (95%CI: 0.71–0.98).

Conclusions

This is the first study comparing the VITACORA-19 and PsAID questionnaires. Either of the two questionnaires could be used to assess HRQoL in PsA. For the first time, VITACORA-19 thresholds are defined that identify the different DAPSA activity categories. A VITACORA-19 score ≥ 66 could be an appropriate treatment target.
Key Points
Health-related quality of life (HRQoL) is an often-underestimated aspect in psoriatic arthritis (PsA).
The PsAID and VITACORA-19 questionnaires offer similar performance for assessing HRQoL in PsA.
A VITACORA-19 ≥ 66 identifies the low disease impact state according to the PsAID.
VITACORA-19 thresholds identifying DAPSA categories are reported.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
The VITACORA- 19 and PsAID questionnaires are equally valid for assessing the impact of psoriatic arthritis on patients' quality of life
Authors
Ignacio Braña
Marta Loredo
Juan Carlos Torre-Alonso
Rubén Queiro
Publication date
21-04-2025
Publisher
Springer International Publishing
Published in
Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-025-07446-4

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar